Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients
Highlights
► New inhaled long-acting muscarinic antagonist (LAMA). ► Randomized, double-blind placebo controlled study. ► Significant increases in trough FEV1 ranging from 150 to 168 mL. ► Significant increases in 0–6 h weighted mean FEV1 ranging 113–211 mL.
Introduction
Bronchodilators remain the mainstay in the treatment of chronic obstructive pulmonary disease (COPD) (GOLD, 2011). Umeclidinium (GSK573719) is a new quinuclidine-based quaternary ammonium inhaled long-acting muscarinic antagonist (LAMA), in development for the once-daily treatment of COPD as a monotherapy and in combination with the long-acting β2-agonist vilanterol.
LAMAs such as tiotropium bromide have previously been shown to provide effective bronchodilation in COPD patients (Casaburi et al., 2002, Vincken et al., 2002) conferring clinically meaningful improvements on trough forced expiratory volume1 (FEV1) and post-bronchodilator FEV1 (Tashkin et al., 2008, Littner et al., 2000). This agent has been shown to improve health-related quality of life to a clinically meaningful extent (Casaburi et al., 2002, Vincken et al., 2002, Tashkin et al., 2008) increase exercise tolerance and reduce exacerbation and hospitalization rate relative to placebo (Tashkin et al., 2008, Niewoehner et al., 2005, Dusser et al., 2006). Tiotropium dissociates more slowly from the M1 and M3 muscarinic receptors than from M2 receptors, such that a prolonged action is obtained (Lipson, 2006).
Previous clinical studies have demonstrated that single and repeat dose administration of the LAMA umeclidinium for up to 14 days is safe and well tolerated in healthy volunteers and patients with COPD (Donohue et al., 2012) with low systemic exposure. The extended residence time of umeclidinium at airway smooth muscle muscarinic receptors leads to sustained bronchodilation over 24 h, meaning that it is suitable for once-daily treatment of COPD (Laine et al., 2011).
The present study was designed to further evaluate the dose–response, safety and pharmacokinetics of umeclidinium in patients with COPD over a greater period of time and in a larger cohort of patients than in previous studies.
Section snippets
Patients and methods (inclusion, exclusion, meds)
Patients were recruited between December 2009 and July 2010 at 21 centres worldwide. All patients gave written informed consent prior to any study related procedures and the protocol was approved by the appropriate institutional review boards and conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki. We recruited men and women aged 40–80 years with a clinical history of COPD (Celli and Macnee, 2004) a smoking history of ≥10 pack years, a
Study population
A total of 421 patients were screened to randomize 288 patients, 285 of whom received at least one dose of study treatment (Fig. 2). Of those included, 264 patients completed the treatment period, as 7% of subjects were withdrawn while receiving treatment. The primary reasons for withdrawal during treatment were AE (1%), COPD exacerbation (3%), protocol deviation (1%), withdrew consent (1%), and met study stopping criteria (<1%). The demographics and baseline characteristics of treatment groups
Discussion
The present data demonstrate that umeclidinium, a new long-acting muscarinic antagonist, provides long-acting bronchodilation in patients with moderate to very severe COPD. No evidence of a dose–response effect was seen. Umeclidinium was well tolerated with no treatment-related serious AEs and low incidence of anticholinergic side effects. These data support the potency of umeclidinium as a bronchodilator, with a duration of action consistent with once-daily dosing; a corresponding reduction in
Conflict of interest
Marc Decramer has been part of Advisory Board for Boehringer-Pfizer, GSK, Nycomed, Altana Novartis and Vectura. He has performed consulting work for Boehringer-Pfizer, GSK, AstraZeneca and Dompé. He also received lecture fees from these companies. All of the above amounted to less than 10,000 euro per annum. He received a research grant of 45,000 euro/year from AstraZeneca.
François Maltais has no conflict of interest to disclose.
Gregory Feldman has received funds as the Principal Investigator in
Acknowledgements
The authors would like to thank the study participants and the participating study personnel. All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors. Statistical support was additionally provided by Lisa Willits at GlaxoSmithKline. Editorial support in the form of editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, referencing and graphic services was provided by Cheryl
References (26)
- et al.
The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group
Chest
(2000) - et al.
Aclidinium bromide provides long-acting bronchodilation in patients with COPD
Pulmonary Pharmacology and Therapeutics
(2010) - et al.
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD
Respiratory Medicine
(2012) - et al.
Pooled clinical trial analysis of tiotropium safety
Chest
(2006) - et al.
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
Respiratory Medicine
(2010) Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
Pulmonary Pharmacology and Therapeutics
(2010)Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?
Thorax
(1993)- et al.
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
European Respiratory Journal
(2002) - et al.
Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
European Respiratory Journal
(2004) - et al.
Mechanisms for isolated volume response to a bronchodilator in patients with COPD
Journal of Applied Physiology
(2000)
The effect of tiotropium on exacerbations and airflow in patients with COPD
European Respiratory Journal
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease
The efficacy and safety of the novel long-acting beta2-agonist vilanterol in COPD patients: a randomized placebo-controlled trial
Chest
Cited by (49)
An Umeclidinium membrane sensor; Two-step optimization strategy for improved responses
2017, TalantaCitation Excerpt :The literature rarely considered the analytical applications for UMEC. To our knowledge, dose-response safety and efficacy along with pharmacokinetic studies were under consideration [15–17]. A validated analytical method has never been reported before.
Different approaches in the treatment of obstructive pulmonary diseases
2015, European Journal of PharmacologyA randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma
2015, Respiratory Medicine